Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Gold Prices Slide as Hawkish Fed and Strong Dollar Weigh on Bullion 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten 
Russia Stocks End Flat as MOEX Index Hits New 52-Week Low; Gold Falls and Oil Mixed 
Judge Dismisses Trump Administration Lawsuit Against Boston Sanctuary City Policy 
Trump Says No Hormuz Strait Tolls During 60-Day Iran Ceasefire 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Trump Lawyers Face Scrutiny After Missing Deadline in $10 Billion BBC Defamation Lawsuit 
Bayer Rules Out Monsanto Spin-Off as Roundup Lawsuits Continue to Mount 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
